DBV Technologies S.A.

Listed Company

DBVTCIK 0001613780NasdaqNon-AcceleratedSmaller ReportingBiological Products, (No Diagnostic Substances)I0FRFY ends Dec 31

Period

FY 2025

Revenue

$5.64M

Net Income

—

Total Assets

—

Equity

—

Shares Out

296.04M

Op. Cash Flow

$-121.18M

Business

DBV Technologies S.A. is a clinical‑stage biopharmaceutical company developing Viaskin, an epicutaneous immunotherapy patch that delivers antigens through intact skin to elicit immune tolerance. Main product candidates include Viaskin Peanut (lead), Viaskin Milk, an eosinophilic esophagitis program, and exploratory vaccination and diagnostic efforts. Key business activities include clinical development and regulatory programs, proprietary patch manufacturing and supply arrangements, and intellectual property management. The company conducts global clinical trials and regulatory interactions in the United States, the European Union and other major markets and relies on contract manufacturers and collaborators for supply and commercialization.

Summary from filing dated 2025-04-11

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Operating income	6	4	16	5	6
Research and development expenses	−117	−89	−60	−76	−70
Sales and marketing expenses	−3	−3	−2	−2	−4
General and administrative expenses	−33	−29	−30	−24	−31
Total Operating expenses	−153	−121	−92	−101	−104
Loss from operations	−147	−117	−76	−97	−99
Financial income (expense)	601,000	3	4	427,000	425,000
Loss before taxes	−146	−114	−73	−96	−98
Income tax	−491,000	−55,000	−7,000	−70,000	381,000
Net loss	−147	−114	−73	−96	−98
Foreign currency translation differences, net of taxes	7	−4	6	−8	−12
Actuarial gains on employee benefits, net of taxes	−408,000	163,000	−38,000	262,000	35,000
Comprehensive loss	−140	−118	−67	−104	−110
Basic Net loss per share attributable to shareholders (in USD per share)	−1.05	−1.17	−0.76	−1.24	−1.78
Diluted Net loss per share attributable to shareholders (in USD per share)	−1.05	−1.17	−0.76	−1.24	−1.78
Weighted average shares outstanding used in computing per share amounts, basic (in shares)	140	97	95	77	55
Weighted average shares outstanding used in computing per share amounts, diluted (in shares)	140	97	95	77	55

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	194	32	141	209	77
Other current assets	19	12	18	14	37
Total current assets	213	44	159	223	114
Property, plant, and equipment, net	10	11	13	15	18
Right-of-use assets related to operating leases	5	6	5	3	7
Intangible assets	22,000	40,000	58,000	10,000	22,000
Other non-current assets	6	4	6	6	7
Total non-current assets	21	21	24	—	—
Total Assets	234	66	183	247	147
Trade payables	41	22	23	14	11
Short-term operating leases	1	654,000	1	2	3
Current contingencies & Employee Benefits	217,000	122,000	4	4	4
Other current liabilities	16	8	9	9	12
Total current liabilities	58	31	37	30	31
Long-term operating leases	5	6	5	1	7
Non-current contingencies & Employee Benefits	2	838,000	935,000	17	7
Total non-current liabilities	7	7	5	23	16
Total Liabilities	65	38	43	52	47
Ordinary shares 0.1 par value; 235,670,864 and 102,847,501 shares authorized, and issued as at December 31, 2025 and December 31, 2024, respectively,	27	12	11	11	7
Additional paid-in capital	541	316	377	458	358
Treasury stock, 74,680 and 266,868 ordinary shares as of December 31, 2025 and December 31, 2024, respectively, at cost	−834,000	−1	−1	—	—
Accumulated deficit	−393	−286	−239	−260	−259
Accumulated other comprehensive income	497,000	905,000	742,000	781,000	519,000
Accumulated currency translation effect	−6	−13	−9	−15	−6
Total Shareholders equity	169	27	140	194	99
Total Liabilities and Shareholder's equity	234	66	183	247	147

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation, amortization and accrued contingencies	3	−925,000	−14	13	8
Expenses related to share-based payments	5	5	6	5	3
Inventory write-downs	16	1	—	—	—
Other elements	−219,000	−3,000	23,000	−7,000	656,000
Decrease (increase) in inventories and work in progress	−16	−1	0	0	0
Decrease (increase) in other current assets	−5	5	−4	21	−9
(Decrease) increase in trade payables	16	272,000	8	3	−8
(Decrease) increase in other current and non-current liabilities	7	366,000	−5	152,000	−8
Change in operating lease liabilities and right of use assets	−203,000	485,000	2	−2	−1
Net cash flow used in operating activities	−121	−104	−80	−56	−108
Change in property, plant, and equipment	−532,000	−2	−677,000	−754,000	−910,000
Change in intangible assets	−6,000	−3,000	0	0	−8,000
Change in non-current other assets	−831,000	2	—	—	—
Net cash flows used in investing activities	−1	−757,000	−808,000	−100,000	−433,000
Treasury shares	476,000	−47,000	−154,000	—	—
Capital increases, net of transaction costs	276	634,000	7	194	794,000
Net cash flows provided by financing activities	276	587,000	7	194	274,000
Effect of exchange rate changes on cash and cash equivalents	8	−4	6	−6	−11
Net (decrease) / increase in cash and cash equivalents	162	−109	−68	132	−119

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro